Meeder Asset Management’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-18
Closed -$2.31K 824
2025
Q2
$2.31K Buy
+18
New +$1.87K ﹤0.01% 805
2025
Q1
Sell
-48
Closed -$4.19K 916
2024
Q4
$4.19K Buy
48
+2
+4% +$183 ﹤0.01% 852
2024
Q3
$4.25K Buy
46
+16
+53% +$1.59K ﹤0.01% 770
2024
Q2
$3.23K Sell
30
-1
-3% -$100 ﹤0.01% 818
2024
Q1
$2.94K Buy
+31
New +$2.66K ﹤0.01% 696
2021
Q4
Sell
-2,227
Closed -$231K 1311
2021
Q3
$231K Hold
2,227
0.01% 677
2021
Q2
$196K Sell
2,227
-19
-0.8% -$1.74K 0.01% 728
2021
Q1
$218K Buy
+2,246
New +$224K 0.01% 703
2020
Q4
Sell
-1,278
Closed -$118K 1899
2020
Q3
$118K Buy
1,278
+360
+39% +$27.7K 0.01% 738
2020
Q2
$73K Buy
918
+748
+440% +$50.6K ﹤0.01% 841
2020
Q1
$10K Buy
170
+168
+8,400% +$10.8K ﹤0.01% 1507
2019
Q4
$0 Sell
2
-92
-98% -$6.89K ﹤0.01% 2252
2019
Q3
$7K Hold
94
﹤0.01% 1634
2019
Q2
$9K Hold
94
﹤0.01% 1478
2019
Q1
$8K Hold
94
﹤0.01% 1293
2018
Q4
$5K Hold
94
﹤0.01% 1398
2018
Q3
$7K Sell
94
-207
-69% -$14.4K ﹤0.01% 1238
2018
Q2
$19.1K Buy
301
+42
+16% +$3.34K ﹤0.01% 969
2018
Q1
$24K Buy
259
+30
+13% +$2.59K ﹤0.01% 846
2017
Q4
$18K Buy
229
+181
+377% +$12.7K ﹤0.01% 950
2017
Q3
$3K Buy
48
+5
+12% +$267 ﹤0.01% 1364
2017
Q2
$2K Buy
43
+5
+13% +$212 ﹤0.01% 1386
2017
Q1
$2K Buy
+38
New +$1.36K ﹤0.01% 1349

Other funds holding BPMC

Meeder Asset Management's BPMC Position: Q3 2025 in Review

Meeder Asset Management sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 18 shares — an estimated $2.31K sold.

Meeder Asset Management first reported a position in BPMC in Q1 2017 and held it in 23 quarters. The position peaked at $231K in Q3 2021. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Meeder Asset Management reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Meeder Asset Management sold 18 Blueprint Medicines shares in Q3 2025, an estimated $2.31K.
  • Meeder Asset Management first reported a position in Blueprint Medicines in Q1 2017 and held it in 23 quarters.
  • Meeder Asset Management's Blueprint Medicines position peaked at $231K in Q3 2021.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Meeder Asset Management's 13F filing for Q3 2025, filed 24 Oct 2025.